FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Met…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an ...
Today

FDA approves Amgen drug for lung cancer with specific mutation

The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened after ...
The Manila Times

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small ...

ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20insWU-KONG28 is the first global randomized ...
News-Medical.Net

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for ...
Nasdaq

ArriVent BioPharma to Host Virtual Investor Event on Firmonertinib Clinical Program for EGFR PACC Mutant NSCLC

ArriVent BioPharma is hosting a virtual investor event to discuss the firmonertinib clinical program, highlighting their commitment to transparency and engagement with stakeholders. Firmonertinib has ...
Zacks Investment Research on MSN

BDTX stock slumps on mixed phase II frontline NSCLC study data

Black Diamond Therapeutics BDTX shares fell 35.8% as investors appeared to take a mixed view of the latest phase II update for the company’s lead candidate, silevertinib, being evaluated for ...

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
News Medical

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...
ascopubs.org

Utilizing TP53 mutation status and initial disease burden at presentation to risk-stratify patients with advanced EGFR-mutated NSCLC treated with osimertinib.

Next generation sequencing (NGS) of malignant effusions and comparison to blood liquid biopsy (ctDNA): A community experience. Celecoxib vs placebo in combination with chemotherapy for non-small cell ...
Nasdaq

ArriVent BioPharma Reports Promising 16-Month Median Progression-Free Survival for Firmonertinib in First-Line NSCLC Patients with EGFR PACC Mutations

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
Medscape

NSCLC Patients Without EGFR Mutations Better on Chemo

For patients with non–small cell lung cancer (NSCLC) that has tested positive for EGFR mutations, treatment with targeted EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib (Tarceva, Osi ...
Medscape

Gefitinib Yields Superior Outcomes vs Chemotherapy in EGFR-Mutation-Positive NSCLC

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...